Lavipharm (Greece) Performance
| LAVI Stock | EUR 0.71 0.01 1.39% |
The company secures a Beta (Market Risk) of -0.0404, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Lavipharm are expected to decrease at a much lower rate. During the bear market, Lavipharm is likely to outperform the market. At this point, Lavipharm SA has a negative expected return of -0.24%. Please make sure to verify Lavipharm's kurtosis, daily balance of power, and the relationship between the skewness and accumulation distribution , to decide if Lavipharm SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lavipharm SA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Price Earnings Ratio | 11.1429 | |
| Total Cashflows From Investing Activities | -1.9 M |
Lavipharm |
Lavipharm Relative Risk vs. Return Landscape
If you would invest 84.00 in Lavipharm SA on September 2, 2024 and sell it today you would lose (13.00) from holding Lavipharm SA or give up 15.48% of portfolio value over 90 days. Lavipharm SA is generating negative expected returns and assumes 1.7617% volatility on return distribution over the 90 days horizon. Simply put, 15% of stocks are less volatile than Lavipharm, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Lavipharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lavipharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lavipharm SA, and traders can use it to determine the average amount a Lavipharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1379
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LAVI |
Estimated Market Risk
| 1.76 actual daily | 15 85% of assets are more volatile |
Expected Return
| -0.24 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lavipharm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lavipharm by adding Lavipharm to a well-diversified portfolio.
Lavipharm Fundamentals Growth
Lavipharm Stock prices reflect investors' perceptions of the future prospects and financial health of Lavipharm, and Lavipharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lavipharm Stock performance.
| Return On Asset | 0.0403 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 59.98 M | |||
| Shares Outstanding | 18.29 M | |||
| Price To Earning | 12.42 X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 41.37 M | |||
| EBITDA | 4.72 M | |||
| Cash And Equivalents | 1.85 M | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 40.54 M | |||
| Book Value Per Share | (0.47) X | |||
| Cash Flow From Operations | 3.82 M | |||
| Earnings Per Share | 0.04 X | |||
| Total Asset | 82 M | |||
| Retained Earnings | (181 M) | |||
| Current Asset | 21 M | |||
| Current Liabilities | 87 M | |||
About Lavipharm Performance
Assessing Lavipharm's fundamental ratios provides investors with valuable insights into Lavipharm's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Lavipharm is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Lavipharm S.A. develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. Lavipharm S.A. was founded in 1911 and is based in Paiania, Greece. LAVIPHARM operates under Drug Manufacturers - Major classification in Greece and is traded on Athens Stock Exchange.Things to note about Lavipharm SA performance evaluation
Checking the ongoing alerts about Lavipharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lavipharm SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lavipharm SA generated a negative expected return over the last 90 days | |
| Lavipharm SA has some characteristics of a very speculative penny stock | |
| Lavipharm SA has high likelihood to experience some financial distress in the next 2 years | |
| About 67.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Lavipharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lavipharm's stock is overvalued or undervalued compared to its peers.
- Examining Lavipharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lavipharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lavipharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lavipharm's stock. These opinions can provide insight into Lavipharm's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Lavipharm Stock Analysis
When running Lavipharm's price analysis, check to measure Lavipharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lavipharm is operating at the current time. Most of Lavipharm's value examination focuses on studying past and present price action to predict the probability of Lavipharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lavipharm's price. Additionally, you may evaluate how the addition of Lavipharm to your portfolios can decrease your overall portfolio volatility.